Home Cart 0 Sign in  
X

[ CAS No. 121-98-2 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
3d Animation Molecule Structure of 121-98-2
Chemical Structure| 121-98-2
Chemical Structure| 121-98-2
Structure of 121-98-2 * Storage: {[proInfo.prStorage]}
Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Quality Control of [ 121-98-2 ]

Related Doc. of [ 121-98-2 ]

Alternatived Products of [ 121-98-2 ]

Product Details of [ 121-98-2 ]

CAS No. :121-98-2 MDL No. :MFCD00008437
Formula : C9H10O3 Boiling Point : -
Linear Structure Formula :- InChI Key :DDIZAANNODHTRB-UHFFFAOYSA-N
M.W : 166.17 Pubchem ID :8499
Synonyms :

Calculated chemistry of [ 121-98-2 ]

Physicochemical Properties

Num. heavy atoms : 12
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 3
Num. H-bond acceptors : 3.0
Num. H-bond donors : 0.0
Molar Refractivity : 44.21
TPSA : 35.53 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -5.7 cm/s

Lipophilicity

Log Po/w (iLOGP) : 2.28
Log Po/w (XLOGP3) : 2.27
Log Po/w (WLOGP) : 1.48
Log Po/w (MLOGP) : 1.64
Log Po/w (SILICOS-IT) : 1.7
Consensus Log Po/w : 1.87

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.47
Solubility : 0.56 mg/ml ; 0.00337 mol/l
Class : Soluble
Log S (Ali) : -2.65
Solubility : 0.37 mg/ml ; 0.00222 mol/l
Class : Soluble
Log S (SILICOS-IT) : -2.59
Solubility : 0.424 mg/ml ; 0.00255 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.17

Safety of [ 121-98-2 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H315-H319-H335 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 121-98-2 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Upstream synthesis route of [ 121-98-2 ]
  • Downstream synthetic route of [ 121-98-2 ]

[ 121-98-2 ] Synthesis Path-Upstream   1~16

  • 1
  • [ 121-98-2 ]
  • [ 829-35-6 ]
Reference: [1] Journal of Medicinal Chemistry, 2001, vol. 44, # 8, p. 1268 - 1285
[2] Magnetic Resonance in Chemistry, 2011, vol. 49, # 10, p. 648 - 654
[3] Angewandte Chemie - International Edition, 2012, vol. 51, # 19, p. 4666 - 4670
[4] Chemical Communications (Cambridge, United Kingdom), 2012, vol. 48, # 92, p. 11307 - 11309,3
  • 2
  • [ 121-98-2 ]
  • [ 149-73-5 ]
  • [ 829-35-6 ]
Reference: [1] Magnetic Resonance in Chemistry, 2003, vol. 41, # 9, p. 689 - 692
  • 3
  • [ 121-98-2 ]
  • [ 1014-25-1 ]
Reference: [1] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
  • 4
  • [ 121-98-2 ]
  • [ 3290-99-1 ]
YieldReaction ConditionsOperation in experiment
96% With hydrazine hydrate In ethanol for 6 h; Reflux 4-Methoxybenzohydrazide was synthesized according to the literature[22]. A mixture of methylmethoxybenzoate (1.66 g, 0.01 mol) andhydrazine hydrate (3.6 ml, 0.06 mol) in ethanol (20 mL) was heatedunder reflux for 6 h. The solvent was removed and the precipitate wasobtained. The solid product was recrystallized with ethanol to give 4-methoxybenzohydrazide as colorless crystals. Yield 96percent, mp 138–139 °C.
90% With hydrazine In methanol; water at 45℃; for 24 h; Example I 4-methoxy-benzoic acid hydrazide A solution of methyl 4-methoxybenzoate, (5.0 g, 0.03 mol) in methanol (20 mL) was treated with hydrazine hydrate (12.0 g, 0.24 mol) and the mixture stirred at 45° C. for 24 hours. The reaction mixture was concentrated and the residue partitioned between EtOAc (50 mL) and water (20 mL). The aqueous layer was extracted with EtOAc (3.x.20 mL), and the combined organic extracts washed with brine (20 mL), dried over Na2SO4, and concentrated to give the desired hydrazide (compound 2) as solid which was crystallized by EtOAc giving white solid 4.50 g in 90percent yield, mp: 134.3° C. (Aldrich, mp: 136-140° C.). 1H NMR (CDCl3) δ 7.73 (d, 2H), 7.38 (s, 1H), 6.94 (d, 2H), 3.85 (s, 3H), 1.69 (s, 2H). 13C NMR (CDCl3) δ 165.5, 159.6, 125.7, 122.0, 111.1, 52.5. Anal. Calcd for C8H10N2O2.1/2H2O: C, 54.84; H, 5.75; N, 15.99. Found: C, 54.57; H, 5.59; N, 15.53.
88% for 4 h; Reflux In the 500 ml round bottom flask is added 53.15g (0.32 µM) 4 - methoxybenzoic acid methyl ester, 300ml50percent hydrazine hydrate reflux 4h, changing device, for the majority of the solvent water pump by reducing pressure, the residual liquid is separated out light yellow crystal after cooling, filtering, drying, and for using ethanol to recrystallize the decolorize with active carbon, to obtain white crystal, yield 88percent
87% With hydrazine hydrate In ethanolReflux General procedure: To a solution of the appropriate methyl benzoate ester (1.0 mmol) in ethanol (30 mL), hydrazine monohydrate (0.15 g, 3.0 mmol) was added. The reaction mixture was heated under reflux overnight. After completion of the reaction, the solvent was evaporated under reduced pressure, and the residue was washed with water (2 x 3 mL), and the obtained solid was filtered and dried to give benzohydrazide derivatives 3a-c.
85% With hydrazine hydrate In methanol for 5 h; Reflux General procedure: To a solution of an appropriate methyl esters17(a–j) (1.0 mmol) in 50 mL of methanol was added 99 percenthydrazine hydrate (4.0 mmol) and the mixture was refluxedfor 5 h up to reaction completed (TLC). After completionof reaction, it was allowed to cool and the obtained solidwas washed with methanol. The crude products wererecrystallized from ethanol.
70% With hydrazine hydrate In ethanol for 5 h; Reflux General procedure: A solution of hydrazine hydrate (20.00 mmol) in 2 mL EtOH was added dropwise to the ester 2 (5.00 mmol). The mixture was refluxed for 5 h and filtered, and the corresponding acid hydrazide 3 was obtained by washing the residue with ice water.
69% With hydrazine hydrate In ethanol for 5 h; Reflux General procedure: Compound 12 (0.013 mol) and 80percent NH2NH2H2O (5 mL) wereadded to EtOH (10 mL), the mixturewas stirred under reflux for 5 h.After being cooled to room temperature, the precipitate was obtainedby filtration, and was dried to give the title compounds,respectively.

Reference: [1] Journal of the American Chemical Society, 2013, vol. 135, # 15, p. 5656 - 5668
[2] Journal of the Chilean Chemical Society, 2012, vol. 57, # 4, p. 1492 - 1496
[3] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2017, vol. 174, p. 272 - 278
[4] European Journal of Medicinal Chemistry, 1985, vol. 20, # 3, p. 257 - 266
[5] Bioorganic and Medicinal Chemistry, 2005, vol. 13, # 16, p. 4842 - 4850
[6] Molecules, 2014, vol. 19, # 1, p. 1286 - 1301
[7] Patent: US2006/189825, 2006, A1, . Location in patent: Page/Page column 6
[8] Letters in Drug Design and Discovery, 2012, vol. 9, # 3, p. 276 - 281
[9] European Journal of Pharmaceutical Sciences, 2002, vol. 15, # 4, p. 367 - 378
[10] New Journal of Chemistry, 2016, vol. 40, # 10, p. 8846 - 8854
[11] Patent: CN106543098, 2017, A, . Location in patent: Paragraph 0040; 0041; 0044; 0045
[12] European Journal of Medicinal Chemistry, 2015, vol. 90, p. 45 - 52
[13] Medicinal Chemistry Research, 2016, vol. 25, # 4, p. 627 - 643
[14] Chemical Communications, 2016, vol. 52, # 46, p. 7387 - 7389
[15] European Journal of Medicinal Chemistry, 2014, vol. 74, p. 73 - 84
[16] European Journal of Medicinal Chemistry, 2015, vol. 104, p. 115 - 126
[17] Journal of Medicinal Chemistry, 2016, vol. 59, # 6, p. 2362 - 2380
[18] Bollettino Chimico Farmaceutico, 1997, vol. 136, # 3, p. 244 - 249
[19] Chemische Berichte, 1961, vol. 94, p. 712 - 724
[20] Pharmazie, 1996, vol. 51, # 2, p. 83 - 88
[21] Bioorganic and medicinal chemistry, 2002, vol. 10, # 3, p. 557 - 560
[22] Journal of Medicinal Chemistry, 2001, vol. 44, # 8, p. 1268 - 1285
[23] Bioorganic and Medicinal Chemistry Letters, 2008, vol. 18, # 4, p. 1297 - 1303
[24] Bioorganic and Medicinal Chemistry Letters, 2006, vol. 16, # 11, p. 2909 - 2914
[25] Bioorganic and Medicinal Chemistry, 2008, vol. 16, # 14, p. 6724 - 6731
[26] Bioorganic and Medicinal Chemistry, 2009, vol. 17, # 8, p. 3028 - 3036
[27] Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry, 2009, vol. 48, # 3, p. 460 - 466
[28] Organic Letters, 2010, vol. 12, # 15, p. 3567 - 3569
[29] Dyes and Pigments, 2010, vol. 84, # 2, p. 153 - 158
[30] Molecules, 2011, vol. 16, # 6, p. 4339 - 4347
[31] Bioorganic and Medicinal Chemistry, 2011, vol. 19, # 21, p. 6293 - 6301
[32] Journal of Molecular Structure, 2011, vol. 1003, # 1-3, p. 52 - 61
[33] Magnetic Resonance in Chemistry, 2011, vol. 49, # 10, p. 648 - 654
[34] Journal of Molecular Structure, 2012, vol. 1011, p. 121 - 127
[35] Arzneimittel-Forschung/Drug Research, 2011, vol. 61, # 8, p. 452 - 457
[36] Angewandte Chemie - International Edition, 2012, vol. 51, # 19, p. 4666 - 4670
[37] Molecules, 2012, vol. 17, # 5, p. 5095 - 5107
[38] Journal of Medicinal Chemistry, 2012, vol. 55, # 17, p. 7525 - 7545
[39] Journal of the Indian Chemical Society, 2012, vol. 89, # 2, p. 281 - 285
[40] Chemical Communications (Cambridge, United Kingdom), 2012, vol. 48, # 92, p. 11307 - 11309,3
[41] European Journal of Medicinal Chemistry, 2013, vol. 61, p. 26 - 40
[42] Bioorganic and Medicinal Chemistry, 2013, vol. 21, # 17, p. 5395 - 5406
[43] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 3943 - 3949
[44] Bulletin of the Korean Chemical Society, 2012, vol. 33, # 12, p. 4180 - 4184
[45] Medicinal Chemistry Research, 2013, vol. 22, # 10, p. 4980 - 4991
[46] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2013, vol. 115, p. 683 - 689
[47] Chemical Biology and Drug Design, 2013, vol. 82, # 5, p. 546 - 556
[48] Comptes Rendus Chimie, 2015, vol. 18, # 12, p. 1320 - 1327
[49] Bioorganic and Medicinal Chemistry Letters, 2014, vol. 24, # 1, p. 192 - 194
[50] Polyhedron, 2014, vol. 68, p. 164 - 171
[51] European Journal of Medicinal Chemistry, 2014, vol. 75, p. 195 - 202
[52] Dalton Transactions, 2014, vol. 43, # 20, p. 7554 - 7560
[53] Medicinal Chemistry Research, 2014, vol. 23, # 4, p. 1661 - 1671
[54] Synthetic Communications, 2014, vol. 44, # 18, p. 2724 - 2737
[55] Bioorganic and Medicinal Chemistry, 2014, vol. 22, # 17, p. 4629 - 4636
[56] Patent: US2015/94337, 2015, A1, . Location in patent: Paragraph 0154; 0155
[57] Spectrochimica Acta - Part A: Molecular and Biomolecular Spectroscopy, 2015, vol. 145, p. 98 - 109
[58] Patent: EP2860176, 2015, A1, . Location in patent: Paragraph 0101; 0102; 0103
[59] Chemical Communications, 2015, vol. 51, # 76, p. 14365 - 14368
[60] Molecules, 2016, vol. 21, # 5,
[61] Bioorganic Chemistry, 2016, vol. 69, p. 48 - 63
[62] Bioorganic and Medicinal Chemistry, 2016, vol. 24, # 21, p. 5611 - 5617
[63] Letters in Drug Design and Discovery, 2016, vol. 13, # 9, p. 968 - 981
[64] Journal of Medicinal Chemistry, 2016, vol. 59, # 21, p. 9942 - 9959
[65] Journal of the Chemical Society of Pakistan, 2016, vol. 38, # 5, p. 864 - 881
[66] Chemical Biology and Drug Design, 2017, vol. 89, # 1, p. 47 - 60
[67] Arkivoc, 2016, vol. 2017, # 2, p. 87 - 106
[68] Oriental Journal of Chemistry, 2017, vol. 33, # 1, p. 335 - 345
[69] Synlett, 2017, vol. 28, # 11, p. 1373 - 1377
[70] Arkivoc, 2017, vol. 2017, # 5, p. 293 - 300
[71] Pharmaceutical Chemistry Journal, 2018, vol. 51, # 10, p. 907 - 917
[72] Bioorganic and Medicinal Chemistry, 2018, vol. 26, # 8, p. 1971 - 1985
[73] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 8, p. 1313 - 1319
[74] Molecular Crystals and Liquid Crystals, 2018, vol. 664, # 1, p. 85 - 94
[75] Bioorganic and Medicinal Chemistry Letters, 2018, vol. 28, # 14, p. 2369 - 2374
  • 5
  • [ 121-98-2 ]
  • [ 141-78-6 ]
  • [ 2881-83-6 ]
Reference: [1] Tetrahedron, 1982, vol. 38, # 9, p. 1203 - 1211
  • 6
  • [ 121-98-2 ]
  • [ 34841-06-0 ]
Reference: [1] Tetrahedron, 2013, vol. 69, # 13, p. 2807 - 2815
  • 7
  • [ 121-98-2 ]
  • [ 67-63-0 ]
  • [ 18228-46-1 ]
  • [ 261930-06-7 ]
  • [ 105-13-5 ]
Reference: [1] Journal of Organic Chemistry, 2001, vol. 66, # 3, p. 862 - 867
  • 8
  • [ 121-98-2 ]
  • [ 6702-50-7 ]
YieldReaction ConditionsOperation in experiment
64%
Stage #1: Heating
Stage #2: With sodium hydrogencarbonate In methanol; water at 50℃;
FIGURES 8A-8C are illustrations of the hydroxylation of arenes mediated by 4,5-dichlorophthaloyl peroxide. To examine the scope of the hydroxylation reaction mediated by 4,5-dichlorophthaloyl peroxide (2), two general sets of reaction conditions were developed. The oxidations are carried out using either 1.3 equivalents of 4,5-dichlorophthaloyl peroxide (2) at 50 °C or 2.5 equivalents heated to 75 °C. Operationally the reaction proceeds without the need for special exclusion of air and the use of commercial grade HFIP is sufficient. Thermogravimetric analysis indicates that 4,5-dichlorophthaloyl peroxide has a point of decomposition at 135 °C. Therefore, all reactions reported are conducted at or below 75 °C. While we have not encountered exothermic reactions, appropriate precautions must be used similar to those for all experiments using peroxides. Isolated yields are given below each entry. The yield in parentheses refers to the starting material recovered. The minor regioisomeric positions are labeled with the respective carbon atom number and, after the major isomer, listed sequentially. Reaction conducted at 0°C. Prior to the addition of 4,5-dichlorophthaloyl peroxide (2) p-toluenesulfonic acid monohydrate (1.0 equiv.) was added to the solution of 3(y).
Reference: [1] Patent: WO2014/158209, 2014, A1, . Location in patent: Page/Page column 10
  • 9
  • [ 121-98-2 ]
  • [ 99-90-1 ]
  • [ 7511-49-1 ]
Reference: [1] Tetrahedron Letters, 2003, vol. 44, # 52, p. 9271 - 9274
  • 10
  • [ 121-98-2 ]
  • [ 25978-74-9 ]
Reference: [1] Journal of Materials Chemistry C, 2016, vol. 4, # 19, p. 4269 - 4277
[2] Patent: CN106146504, 2016, A,
[3] Patent: EP3284743, 2018, A1,
  • 11
  • [ 121-98-2 ]
  • [ 38493-59-3 ]
Reference: [1] Tetrahedron, 2013, vol. 69, # 13, p. 2807 - 2815
  • 12
  • [ 121-98-2 ]
  • [ 40757-20-8 ]
Reference: [1] Justus Liebigs Annalen der Chemie, 1845, vol. 56, p. 308[2] Annales de Chimie (Cachan, France), 1845, vol. <3> 14, p. 486
  • 13
  • [ 121-98-2 ]
  • [ 73873-61-7 ]
Reference: [1] Journal of the American Chemical Society, 1957, vol. 79, p. 3098,3101
  • 14
  • [ 121-98-2 ]
  • [ 5446-02-6 ]
YieldReaction ConditionsOperation in experiment
65% With oxone; Ru(MesCO2)(4,4'-dibromobipyridine)(p-cymene); trifluoroacetic acid; trifluoroacetic anhydride In 1,2-dichloro-ethane at 110℃; for 12 h; Sealed tube; Green chemistry General procedure: The Ru(MesCO2)(L) (p-cymene) [L- 2,2’-bypyridine or 4,4’-dibromobipyridine] (2.5 molpercent), oxidant (2.0 eq) and ester (1.0 eq) were added to a sealed tube. Following that, trifluoroacetic acid (TFA) and trifluoroacetic anhydride (TFAA) in the ratio of 0.6 ml: 0.4 were added. The reaction mixture was kept on a pre-heated bath at 110°C and stirred until its completion. It was continuously monitored by TLC. Ice water was added to quench the reaction mixture and it was extracted with dichloromethane. The organic layer was dried over Na2SO4 and rota-evaporated. Finally the residue was purified by silica gel column chromatography to give corresponding products.
Reference: [1] Tetrahedron Letters, 2017, vol. 58, # 38, p. 3743 - 3746
  • 15
  • [ 99-50-3 ]
  • [ 89-86-1 ]
  • [ 149-91-7 ]
  • [ 99-10-5 ]
  • [ 303-38-8 ]
  • [ 490-79-9 ]
  • [ 99-06-9 ]
  • [ 69-72-7 ]
  • [ 74-88-4 ]
  • [ 99-96-7 ]
  • [ 2150-41-6 ]
  • [ 606-45-1 ]
  • [ 5368-81-0 ]
  • [ 121-98-2 ]
  • [ 2150-38-1 ]
  • [ 1916-07-0 ]
  • [ 2150-42-7 ]
  • [ 2150-40-5 ]
  • [ 2150-37-0 ]
Reference: [1] Chemical Communications, 2014, vol. 50, # 14, p. 1694 - 1697
  • 16
  • [ 79-20-9 ]
  • [ 121-98-2 ]
  • [ 22027-50-5 ]
Reference: [1] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1910, vol. 150, p. 540[2] Bulletin de la Societe Chimique de France, 1912, vol. <4> 11, p. 64
[3] Bulletin de la Societe Chimique de France, 1913, vol. <4> 13, p. 279
[4] Bulletin de la Societe Chimique de France, 1912, vol. <4> 11, p. 31[5] Comptes Rendus Hebdomadaires des Seances de l'Academie des Sciences, 1910, vol. 150, p. 539
Same Skeleton Products
Historical Records

Similar Product of
[ 121-98-2 ]

Chemical Structure| 93627-95-3

A1269594[ 93627-95-3 ]

Methyl 4-Methoxy-[7-13C]-benzoate

Reason: Stable Isotope

Related Functional Groups of
[ 121-98-2 ]

Aryls

Chemical Structure| 5368-81-0

[ 5368-81-0 ]

Methyl 3-methoxybenzoate

Similarity: 0.98

Chemical Structure| 71590-08-4

[ 71590-08-4 ]

3-Methoxy-5-(methoxycarbonyl)benzoic acid

Similarity: 0.98

Chemical Structure| 94-30-4

[ 94-30-4 ]

Ethyl 4-methoxybenzoate

Similarity: 0.96

Chemical Structure| 19520-74-2

[ 19520-74-2 ]

Methyl 3-hydroxy-5-methoxybenzoate

Similarity: 0.96

Chemical Structure| 2150-37-0

[ 2150-37-0 ]

Methyl 3,5-dimethoxybenzoate

Similarity: 0.96

Ethers

Chemical Structure| 5368-81-0

[ 5368-81-0 ]

Methyl 3-methoxybenzoate

Similarity: 0.98

Chemical Structure| 71590-08-4

[ 71590-08-4 ]

3-Methoxy-5-(methoxycarbonyl)benzoic acid

Similarity: 0.98

Chemical Structure| 94-30-4

[ 94-30-4 ]

Ethyl 4-methoxybenzoate

Similarity: 0.96

Chemical Structure| 19520-74-2

[ 19520-74-2 ]

Methyl 3-hydroxy-5-methoxybenzoate

Similarity: 0.96

Chemical Structure| 2150-37-0

[ 2150-37-0 ]

Methyl 3,5-dimethoxybenzoate

Similarity: 0.96

Esters

Chemical Structure| 5368-81-0

[ 5368-81-0 ]

Methyl 3-methoxybenzoate

Similarity: 0.98

Chemical Structure| 71590-08-4

[ 71590-08-4 ]

3-Methoxy-5-(methoxycarbonyl)benzoic acid

Similarity: 0.98

Chemical Structure| 94-30-4

[ 94-30-4 ]

Ethyl 4-methoxybenzoate

Similarity: 0.96

Chemical Structure| 19520-74-2

[ 19520-74-2 ]

Methyl 3-hydroxy-5-methoxybenzoate

Similarity: 0.96

Chemical Structure| 2150-37-0

[ 2150-37-0 ]

Methyl 3,5-dimethoxybenzoate

Similarity: 0.96